Success Metrics

Clinical Success Rate
87.7%

Based on 50 completed trials

Completion Rate
88%(50/57)
Active Trials
2(3%)
Results Posted
72%(36 trials)
Terminated
7(10%)

Phase Distribution

Ph early_phase_1
2
3%
Ph not_applicable
2
3%
Ph phase_4
19
26%
Ph phase_1
5
7%
Ph phase_2
18
25%
Ph phase_3
19
26%

Phase Distribution

7

Early Stage

18

Mid Stage

38

Late Stage

Phase Distribution65 total trials
Early Phase 1First-in-human
2(3.1%)
Phase 1Safety & dosage
5(7.7%)
Phase 2Efficacy & side effects
18(27.7%)
Phase 3Large-scale testing
19(29.2%)
Phase 4Post-market surveillance
19(29.2%)
N/ANon-phased studies
2(3.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

50 of 61 finished

Non-Completion Rate

18.0%

11 ended early

Currently Active

2

trials recruiting

Total Trials

72

all time

Status Distribution
Active(5)
Completed(50)
Terminated(11)
Other(6)

Detailed Status

Completed50
Terminated7
unknown6
Withdrawn4
Not yet recruiting3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
72
Active
2
Success Rate
87.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.1%)
Phase 15 (7.7%)
Phase 218 (27.7%)
Phase 319 (29.2%)
Phase 419 (29.2%)
N/A2 (3.1%)

Trials by Status

terminated710%
unknown68%
withdrawn46%
completed5069%
recruiting23%
not_yet_recruiting34%

Recent Activity

Clinical Trials (72)

Showing 20 of 72 trialsScroll for more
NCT06794866Phase 3

A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

Completed
NCT05878951Phase 2

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

Recruiting
NCT07535723Not Applicable

Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine

Not Yet Recruiting
NCT06783621Phase 4

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Completed
NCT06583343Phase 4

Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy

Completed
NCT07220382Phase 4

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Recruiting
NCT06834789Phase 1

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Completed
NCT06902805Phase 2

Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.

Not Yet Recruiting
NCT05134649Phase 3

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
NCT04949399Phase 3

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Completed
NCT05320393Phase 2

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Completed
NCT04994535Phase 3

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
NCT06530524Phase 2

Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery

Not Yet Recruiting
NCT06499688Phase 3

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Completed
NCT06003049Phase 2

A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD

Completed
NCT05284019Phase 4

Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated
NCT05807412Early Phase 1

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Completed
NCT03055767Phase 2

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

Completed
NCT05463965Phase 3

A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Completed
NCT05743634Phase 1

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Completed

Drug Details

Intervention Type
DRUG
Total Trials
72